skate puck
result line pre-announce continu
see guidanc achiev share
gainer debat shift competit concern
expans drive out-performance
remain overweight pt
result guidanc line pre-announc nevro
report revenu cc growth includ us revenu
growth ou revenu cc growth
reiter top-line guidanc item line
preliminari result januari market model indic like took
bp us share sequenti bp pleas see
exhibit full reconcili result exhibit market
guidanc look achiev sale guidanc
impli growth compar growth appear
achiev risk-adjust senza ii approv januari mri safe
approv help margin applaud manag choic
move away guid rep product metric led
inconsist messag past estim us
y/i growth repres pt us share gain versu pt
year expect new sale leadership continu improv momentum seen
greater commerci enthusiasm among physician data-
driven multipl market expans approach continu elev market
growth given new technolog expans initi incumb market
push opioid crisi
season factor top-line estim
reflect y/i growth sequenti declin
annual revenu note across incumb
abbott boston annual revenu came first
fiscal quarter season current consensu estim reflect
y/i growth revenu midpoint comfort
modestli consensu estim
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
us market acceler broader
major player report estim us market grew
underli momentum improv pt follow pt
slowdown dynam larg driven whose us
franchis estim high-teen hurrican impact
high-singl digit intelli launch overal market like grew
versu annual basi abbott pt
pt gain share pt boston pt lost
share year
us market continu grow mid-teen
take share expect low mid teen market
growth consist incumb commentari nan continu
see us growth mid-teen next year given new technolog expans
initi incumb market push opioid crisi market model
project growth share dynam play similar abbott
pt pt gain share pt boston
pt continu share donor albeit lesser degre given abbott
slowdown intelli wavewrit launch respect
competit respons build view addit market
senza superior discuss follow nan despit
variou attempt multipl clinic commerci set discredit hf
therapi sunburst whisper proco singl
random data set rival efficaci durabl senza-rct
howev data import evidenc share gain
salesforc execut play larger role data-intens
market cardiolog incumb respons burst intelli
shown effect given broader market driver discuss see
incumb push boston addit market
see rel insul
beyond competit respons skate puck go
expans initi expect invest debat shift
competit expans catalyst materi clinician
enthusiasm new indic high expect expand
label year upper limb neck uln market
tradit tonic fail data senza-pdn pain diabet
neuropathi market nan data senza-nsrbp
non-surg back potenti market mid/lat enrol
updat well addit clinic studi possibl catalyst
blind incumb push sale turn
discount similar growth peer fear may reflect dilig
suggest expans initi materi driver
physician enthusiasm near term
remain overweight price target move continu see
abl gain share face stronger competit concern
competit nois fade see debat shift tam
expans stori compani better posit dcf-deriv price
target move primarili lower structur tax rate peak
termin assumpt includ oper margin ww share
us share continu see ww us
market grow compound-annual-growth-rate net dcf base
price target wacc termin growth rate move versu
prior base busi expans initi
price target reflect ev/sal turn discount
median high-growth smid comp
senza uptak higher us spinal cord stimul market share drive upsid
senza uptak higher us spinal cord stimul market share drive upsid
price target deriv discount cash flow
valuat assum ww termin share margin
wacc yield today one year
ad valu expans place price target
share gain expans continu rapid share gain allow
captur market share time margin reach addit
make substanti progress expans opportun
painlessli disrupt captur us market
gain share face increas competit appear track
reach us share time expans opportun non-surg
cohort diabet neuropathi chronic upper extrem pain continu
competit respons creat headwind progress date low-hang
fruit futur uptak prove challeng market prove
sensit market clinic data at-risk competit launch caus
disrupt market us market share remain flat top
high teen valuat contract
guidanc look achiev us
believ set continu take share
us market year debat
shift competit abbott
boston tam
expans better
clinic effort materi expand
tam upper limb neck uln
pain diabet neuropathi pdn non-
surgic back abdomin pain earli
continu believ ip around
senza technolog valid
enforc risk boston
action challeng handicap
updat come octob
pt ww share increas
revenu
pt us share increas
revenu
pt us market growth assum
pro rata share increas revenu
bp
competit launch data on-going
risk achiev price
acceler competitor product
develop product uptak
current rep/physician relationship
stronger anticip
confid ip posit
patent litig may key risk time
million except ep
sale
sale
sale
sale
sale
sale
accret redeem convert prefer stock redempt valu
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
accumul comprehens loss
dollar million except per share data
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc transact
purchas short-term invest
proce matur short-term invest
chang restrict cash
proce issuanc common stock underwritten public offer
proce issuanc convert note
convert note initi issuanc discount debt issuanc costs-
proce issuanc warrant
purchas convert note hedg
repay debt
purchas common stock proce issuanc common stock stock option exercis
begin period
end period
million
